Keywords: Merck & Co, Simponi, Ankylosing spondylitit, Bristol-Myers Squibb, Orencia, Rheumatoid arthritis, UK, NICE

UK’s NICE recommends Merck & Co’s Simponi but not B-MS’s Orencia

Article | 26 August 2011

Print This

There was mixed news for US drug majors Merck & Co (NYSE: MRK) and Bristol-Myers Squibb (NYSE: BMY) this week ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in